{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.8","upperLimit":"100.0","value":"100"},{"groupId":"OG001","lowerLimit":"54.1","upperLimit":"100.0","value":"100"},{"groupId":"OG002","lowerLimit":"42.1","upperLimit":"99.6","value":"86"},{"groupId":"OG003","lowerLimit":"22.3","upperLimit":"95.7","value":"67"},{"comment":"No participants achieved B symptom resolution","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"No participants achieved B symptom resolution","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"B symptom resolution rate per investigator was defined as the percentage of subjects with lymphoma-related B symptoms at baseline who achieved resolution of all B symptoms at any time during the treatment period.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin (BV) monotherapy in adults age 60 and above with classical Hodgkin Lymphoma (cHL). BV (1.8 mg/kg) was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part A"},{"description":"BV in combination with dacarbazine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Dacarbazine (375 mg/m\\^2) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Part B"},{"description":"BV in combination with bendamustine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Bendamustine (70 mg/m\\^2) was administered as an IV infusion on Day 1 and Day 2 of each 21-day cycle.","id":"OG002","title":"Part C"},{"description":"BV in combination with nivolumab as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Nivolumab (3 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Part D"},{"description":"BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Part E"},{"description":"BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Part F"}],"paramType":"NUMBER","populationDescription":"Subjects with any B symptom at baseline.","reportingStatus":"POSTED","timeFrame":"Up to 42 weeks","title":"B Symptom Resolution Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}